Skye Bioscience Inc. released a corporate presentation highlighting its obesity and metabolic disease program centered on nimacimab, a peripherally restricted CB1-inhibiting antibody, including development plans for use in combination with semaglutide. The presentation summarizes Phase 2a CBeyond data showing 13% weight loss at 26 weeks for nimacimab plus semaglutide versus semaglutide alone (p=0.03), and interim extension data indicating 22.3% total weight loss at 52 weeks in the combination group with no plateau observed. It also reports reduced post-treatment weight rebound over a 13-week off-therapy follow-up (~17.8% for the combination vs. ~37.3% for semaglutide alone) and notes tolerability observations in the combination arm, including no additive gastrointestinal burden and no neuropsychiatric adverse events reported. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief on February 22, 2026, and is solely responsible for the information contained therein.